Irene Tsung

Irene Tsung

Oncology
1500 E Medical Center Dr
Floor B1 Reception E
Ann Arbor, MI 48109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry.

Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry.

Journal: European urology open science
Published: February 11, 2026

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Journal: Clinical genitourinary cancer
Published: December 02, 2025

Reply to "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer".

Reply to "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer".

Journal: Cancer
Published: October 09, 2025

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Journal: JCO precision oncology
Published: September 16, 2025

Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.

Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.

Journal: Clinical genitourinary cancer
Published: July 29, 2025

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Journal: The oncologist
Published: June 09, 2025

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Journal: Urologic oncology
Published: May 19, 2025

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

Journal: European urology
Published: May 07, 2025

Controversies in metastatic hormone-sensitive prostate cancer.

Controversies in metastatic hormone-sensitive prostate cancer.

Journal: Cancer
Published: February 26, 2025

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.

Journal: The Journal of urology
Published: November 01, 2022

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.

Journal: Frontiers in oncology
Published: July 02, 2022

Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.

Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.

Journal: Immunotherapy
Published: March 02, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026